12-24 Hours
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
Safety Advices
বাংলা
English
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Nibalap 250. Please consult your doctor.
CONSULT YOUR DOCTOR
Nibalap 250 is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
UNSAFE
Nibalap 250 is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
UNSAFE
Nibalap 250 may cause side effects which could affect your ability to drive.
CAUTION
Nibalap 250 should be used with caution in patients with severe kidney disease. Dose adjustment of Nibalap 250 may be needed. Please consult your doctor.
Limited information is available on the use of Nibalap 250 in these patients. No dose adjustment is recommended in patients with mild to moderate kidney disease.
CAUTION
Nibalap 250 should be used with caution in patients with liver disease. Dose adjustment of Nibalap 250 may be needed. Please consult your doctor.
Limited information is available on the use of this medicine in patients with the severe liver disease.
Medicine Overview of Nibalap 250mg Tablet
Introduction
Nibalap 250 is used in the treatment of breast cancer. It shows its working by stopping or slowing down the growth of cancer cells. It is either used alone or in combination with some other medicine to cure advanced stage of breast cancer. Nibalap 250 should be taken on an empty stomach or should be taken one hour before or 2 hour after meal. You should continue to take it as long as your doctor advises it. The duration of treatment varies according to your need and response to treatment. You should take it exactly as your doctor has advised....
... Show moreUses of Nibalap 250
- Breast cancer
Side effects of Nibalap 250
Common
- Abdominal pain
- Back pain
- Breathing problems
- Constipation
- Cough
- Diarrhea
- Fatigue
- Headache
- Hot flashes
- Increased bilirubin in the blood
- Insomnia (difficulty in sleeping)
- Joint pain
- Liver damage
- Loss of appetite
- Mucosal inflammation
- Nausea
- Pain in extremity
- Rash
- Stomatitis (Inflammation of the mouth)
- Vomiting
- Weakness
- Weight gain
How to use Nibalap 250
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Nibalap 250 is to be taken empty stomach.
How Nibalap 250 works
Nibalap 250 is an anti-cancer medication. This works against the HER2 (human epidermal growth factor receptor protein) receptors and EGFRs (epidermal growth factor receptor) which is responsible for the over-proliferation of cells. This is how it inhibits the growth of cancerous cells causing downstream signaling pathways.
Quick Tips
- It should be taken 1 hour before or after the meal, preferably at the same time every day.
- Diarrhea may occur as a side effect. Drink plenty of fluids and inform your doctor if it doesn't stop or if you find blood in your stools.
- Use a reliable contraceptive method to prevent pregnancy while you are taking this medicine and for a month after you stop taking it.
- Monitor your blood pressure regularly while taking this medication. Inform your doctor if you notice symptoms of very high blood pressure such as severe headache, confusion, problems with your eyesight, nausea or vomiting.
- It may cause serious bleeding problem. Inform your doctor if you get headaches, stomach pain or if you notice blood in your urine or stools.
- Do not take this medicine if you are pregnant, planning to conceive or breastfeeding.
Brief Description
Indication
Breast cancer
Administration
Should be taken on an empty stomach. Take at least 1 hr before or 1 hr after a meal. Do not eat/drink grapefruit products.
Adult Dose
Oral Breast Cancer HER2-overexpressing metastatic breast cancer Indicated in combination with capecitabine for treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab 1250 mg PO qDay on Days 1-21 continuously in combination with capecitabine (2000 mg/m²/day PO divided q12hr) on Days 1-14 in a repeating 21-day cycle Hormone-positive & HER2-positive advanced breast cancer Indicated in combination therapy with letrozole for treatment of postmenopausal women with hormone receptor-positive and HER2-positive breast cancer for whom hormonal therapy is indicated 1500 mg PO qDay administered continuously...
... Show moreChild Dose
Safety and efficacy not established
Contraindication
Hypersensitivity to lapatinib ditosylate
Mode of Action
Kinase inhibitor, blocks EGF-receptor HER2 kinase; tyrosing kinase inhibition possibly blocks angiogenesis and cellular proliferation.
Precaution
Evaluate left ventricular ejection fraction (LVEF) prior to treatment. Moderate or severe hepatic impairment. Patients who have or may develop QTc prolongation, including those w/ hypokalaemia or hypomagnesemia. Monitor liver function & pulmonary symptoms indicative of interstitial lung disease/pneumonitis. Pregnancy & lactation.
Lactation: Do not nurse
Side Effect
>10% (lapatinib+capecitabine)
Diarrhea (65%),Anemia (56%),Hand-foot synd (53%),Increased LFTs (37-49%),Nausea (44%),Rash (28%),Vomiting (26%),Pain (23%),Neutropenia (22%),Thrombocytopenia (18%),Mucositis (15%),Stomatitis (14%),Dyspnea (12%),Dyspepsia (11%),Insomnia (10%)
1-10%
Insomnia
Interaction
Increased conc w/ CYP3A4 inhibitors (eg ketoconazole, itraconazole or grapefruit juice), midazolam, irinotecan & digoxin. Decreased conc w/ CYP3A4 inducers (eg rifampin, carbamazepine, phenytoin) & proton-pump inhibitors (eg esomeprazole). Altered pharmacokinetics w/ P-glycoprotein, breast cancer resistance protein (BCRP) inhibitors & inducers, topotecan & rosuvastation. Increased incidence & severity of adverse events w/ paclitaxel & docetaxel. CYP3A4 or CYP2C8 substrates.
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
